Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors bought 29,275 call options on the company. This represents an increase of approximately 43% compared to the average daily volume of 20,478 call options.
Wall Street Analysts Forecast Growth
RXRX has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $7.00.
Read Our Latest Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Performance
RXRX stock traded up $0.13 during trading hours on Thursday, reaching $5.72. The stock had a trading volume of 28,539,701 shares, compared to its average volume of 16,444,098. The stock has a 50-day simple moving average of $4.82 and a 200 day simple moving average of $6.09. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11. The stock has a market capitalization of $2.33 billion, a PE ratio of -3.23 and a beta of 0.91. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.39) EPS. Analysts predict that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.
Institutional Trading of Recursion Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaQuest LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth about $36,000. GAMMA Investing LLC boosted its holdings in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after buying an additional 2,026 shares during the period. Farther Finance Advisors LLC raised its stake in Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. NewEdge Advisors LLC raised its stake in Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after purchasing an additional 2,387 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $54,000. Institutional investors own 89.06% of the company's stock.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Articles
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.